poster

Safety and Tolerability of Brexpiprazole for the Treatment of Borderline Personality Disorder: a 12-Week, Flexible-Dose, Open-Label Extension Study

Abstract: Background: Atypical antipsychotics may be efficacious in the treatment of borderline personality disorder (BPD). This study assessed the safety, tolerability and efficacy of br...

01/19/2023

Efficacy and Safety of Iclepertin (BI 425809) in Patients With Schizophrenia: CONNEX, a Phase III Randomized Controlled Trial Program

Abstract: Introduction No effective pharmacological treatments are available for cognitive impairments in schizophrenia. Iclepertin (BI 425809), an inhibitor of glycine transporter-1, enh...

01/19/2023

Combining Pharmacotherapy of Iclepertin (BI 425809) With Computerized Cognitive Training in Patients With Schizophrenia: Baseline Data and Patient Demographics From an Ongoing Phase II Trial

Abstract: Introduction Iclepertin (BI 425809), a novel glycine transporter-1 inhibitor, had pro-cognitive effects in patients with schizophrenia in a Phase II trial; however, the effects ...

01/19/2023

Elevating the Patient Voice in Schizophrenia: From Publication to Practice

Abstract: Rationale Patients and clinicians may have different expectations concerning their priorities and perspectives for treating schizophrenia. For example, patient accounts of livin...

01/19/2023

Budget Impact of Aripiprazole 2-Month Ready to Use Long-Acting Injectable for Adult Patients with Schizophrenia in the United States

Abstract: Background Aripiprazole 2-Month Ready to Use (ARI 2M RTU) formulation is a long-acting injectable (LAI) currently in development as a treatment for schizophrenia and maintenance...

01/19/2023

Updated Cost-Effectiveness Analysis of Brexpiprazole for Adjunctive Treatment in Major Depressive Disorder in the United States

Abstract: Background: A 2017 published cost-effectiveness analysis of brexpiprazole compared to quetiapine-150 mg/day, quetiapine-300 mg/day, olanzapine/fluoxetine 50mg-12mg/day and antid...

01/19/2023

Prevalence of Pharmacogenomic Actionability in >11,000 Patients Receiving Psychiatric Care

Abstract: Introduction: Most patients with major depressive disorder (MDD) fail first-line antidepressant treatment. Pharmacogenomic (PGx) testing may improve drug selection and/or dosing...

01/19/2023

Excessive Daytime Sleepiness in a Real-World Study of Participants With OSA With or Without Comorbid Depression

Abstract: Background: Obstructive sleep apnea (OSA) is a common sleep disorder that is often associated with medical and psychiatric comorbidities. Patients with OSA experience many sympt...

01/19/2023

Effect of PH94B and Steroid Hormones on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects

Abstract: Background and Introduction: PH94B is an investigational pherine nasal spray thought to regulate the olfactory-amygdala circuits of fear and anxiety without direct GABA-A recept...

01/19/2023

Economic Burden and Healthcare Resource Utilization Among Individuals with Major Depressive Disorder Utilizing Anti-Anxiety Medications in the United States

Abstract: Background: Anxiety is a prevalent symptom among patients with major depressive disorder (MDD). MDD patients with anxiety symptoms frequently experience more severe depression, ...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products